How global MS prevalence is changing: A retrospective chart review in the United Arab Emirates

Schiess, Nicoline; Huether, Katherine; Fatafta, Taghreed; Fitzgerald, Kathryn C.; Calabresi, Peter A.; Blair, Iain; Alsaadi, Taoufik; Szólics, Miklós

doi:10.1016/j.msard.2016.07.005

Cited by 36 publications

(25 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent paper in 2016 Schiess et al reported the prevalence of MS among Emiratis in Abu Dhabi (UAE) to be 57.09%, which is similar to another study from Dubai (UAE) in 2011 which determined the prevalence of 54.77% for the disease [26,27].…”

Section: Introductionsupporting

confidence: 57%

Hypovitaminosis D Status in Newly Diagnosed Cases of MS versus Control Group

Saeedan¹,

Ko²,

Chirakkara³

et al. 2017

J Mult Scler

View full text Add to dashboard Cite

Background: Hypovitaminosis D is amongst those strongly suggested risk factors for multiple sclerosis (MS). Although the association of vitamin D deficiency with MS has been established in several studies in recent years, there are not many studies to assess and compare the degree of Hypovitaminosis D status of newly diagnosed patients with multiple sclerosis versus control group worldwide, especially in UAE.

show abstract

Section: Introductionsupporting

confidence: 57%

Hypovitaminosis D Status in Newly Diagnosed Cases of MS versus Control Group

Saeedan¹,

Ko²,

Chirakkara³

et al. 2017

J Mult Scler

View full text Add to dashboard Cite

show abstract

“…However, the prevalence among Saudi nationals only was comparable to the prevalence reported in the above-mentioned studies. (15)(16)(17)(18) Moreover, when compared to other western regions, the prevalence in Saudi Arabia is considered low. The prevalence in other western countries was reported as high as 98.4/100,000, 106.6/100,000, 170.9/100,000 and 179.9/100,000 in central Italy, Italy, France, Columbia and Canada respectively.…”

Section: Discussionmentioning

confidence: 99%

Rising Prevalence of Multiple Sclerosis in Saudi Arabia, a Descriptive Study

Jumah

Bunyan

Otaibi

et al. 2019

Preprint

View full text Add to dashboard Cite

Introduction In 2015, the first nationwide, multi-center MS registry was initiated in Saudi Arabia mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS. Method The registry included patients with confirmed MS diagnosis according to the 2010 McDonald Criteria. It aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics, family history, and treatments. All included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region. Results As of September 2018, the registry has included 20 hospitals and has collected comprehensive data on 2,516 patients from those hospitals, with median age 32(Range: 11-63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the overall prevalence of MS at the country level to be 40.40/100,000 population and 61.95/100,000 Saudi nationals. 77.5% were 40 years of age or younger. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia Conclusion The prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia’s projected prevalence of MS through this national study is 40.40/100,000 population, putting them above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia.

show abstract

“…Although a possible increase in prevalence of MS in the Middle East has been noted [8,19], few studies on the safety, efficacy or use of MS medications have been conducted in the Middle East. Two studies examining the safety and efficacy of fingolimod in Kuwait [20] and Lebanon [21] have been published.…”

Section: Resultsmentioning

confidence: 99%

“…A retrospective chart review on people with MS followed at four large government hospitals in Abu Dhabi, UAE was conducted in 2014 by Schiess and was subsequently extended to include people with MS followed until the end of 2016 [8].…”

Section: Methodsmentioning

confidence: 99%

The Rapidly Changing Landscape of Multiple Sclerosis Immunomodulatory Therapy: A Retrospective Chart Review in the United Arab Emirates

Schiess¹,

Holroyd²,

Aziz³

et al. 2017

J Mult Scler

Self Cite

View full text Add to dashboard Cite

The past 6 years have demonstrated a dramatic change in the landscape of immunomodulatory treatment for multiple sclerosis. Prior to 2010, there were no approved FDA oral immunomodulatory medications available. Since then, three new oral medications have been approved in addition to the newly approved alemtuzumab and ocrelizumab. This has dramatically changed the treatment options for MS patients. The older injectable agents -beta-interferons and glatiramer acetate are slowly being replaced. While data exists in the literature regarding the use of new medications in the west, there is little published data about the use of these new medications in the Middle East and, none, to our knowledge, in the United Arab Emirates (UAE). We conducted a retrospective chart review of four major government hospitals in Abu Dhabi looking at the types of MS in the Emirate, the use of different immunomodulatory treatment and the changes in prescribed medications between 2014 and 2016. A total of 328 people with MS were identified for the study. The proportion of participants receiving injections or infusions significantly (p=0.0013) dropped from 53% (128) in 2014 to 42.7% (102)

show abstract

How global MS prevalence is changing: A retrospective chart review in the United Arab Emirates

Cited by 36 publications

References 18 publications

Hypovitaminosis D Status in Newly Diagnosed Cases of MS versus Control Group

Hypovitaminosis D Status in Newly Diagnosed Cases of MS versus Control Group

Rising Prevalence of Multiple Sclerosis in Saudi Arabia, a Descriptive Study

The Rapidly Changing Landscape of Multiple Sclerosis Immunomodulatory Therapy: A Retrospective Chart Review in the United Arab Emirates

Contact Info

Product

Resources

About